#Canada #Vancouver #IM Cannabis #Adjupharm GmbH #Space Defense Innovations

IM Cannabis Corp. Reveals Q3 2026 Financial Outcomes

On November 13, 2026, IM Cannabis Corp. (NASDAQ: IMCC) announced its financial results for the third quarter and the first nine months of the year, marking notable changes in their revenue streams and strategic direction. The report reveals that for the third quarter, revenues totaled C$1.65 million, a significant drop from C$5.08 million during the same quarter the previous year. The company faced a gross loss of C$35,000, coupled with a net loss of C$7.08 million, reflecting an increase from the net loss of C$3.87 million in Q3 2025.

For the initial nine months of 2026, the revenue reached C$8.96 million, down from C$15.77 million during the corresponding period of 2025. Additionally, the net loss for this period soared to C$13.93 million, up from C$3.88 million in 2025. These financial results indicate a period of substantial adjustment and restructuring for the company, highlighting challenges within the market environment as it continues to evolve.

Strategic Acquisitions and Divestments

Amid these financial hurdles, IM Cannabis has also made strategic decisions about its future growth. In a significant move, the company announced a non-binding agreement to acquire a 51% stake in Space Defense Innovations LLC (SDI), a Polish entity engaged in the unmanned aerial systems sector through its subsidiary, BlueAero Group. This acquisition is currently under negotiation, with IM Cannabis working to finalize the share purchase agreement with SDI’s shareholders. This expansion into the technology sector is a noteworthy shift for IM Cannabis, indicating an interest in diversifying its business model beyond medical cannabis.

In a separate yet equally important decision, the company finalized the sale of its European operations, which included its subsidiary Adjupharm GmbH, to Slil.com Holding Ltd. on September 29, 2026. This transaction was part of a larger restructuring initiative, allowing the company to streamline its operations and focus on its core Israeli market. The deal involved an advance payment of C$3 million and acceptance of specific liabilities totaling up to C$9.4 million, but it is expected to enhance shareholder equity by roughly C$3 million.

Future Outlook for IM Cannabis

With these financial results and operational changes, IM Cannabis is positioning itself for future growth and resilience. The company is actively evaluating additional opportunities while maintaining a focus on its retained medical cannabis operations in Israel. Their ecosystem leverages years of proprietary data and patient insights to better serve the medical cannabis market, reinforcing their commitment to quality and safe delivery of products to patients.

Forward-looking statements indicate a cautious optimism regarding anticipated effects of the current strategies on the company’s financial health. Potential risks persist, such as market volatility, regulatory changes, and operational challenges, particularly as the global landscape continues to shift.

As of now, the full interim financial statements and comprehensive management analysis are accessible through SEDAR+ and EDGAR, offering more detailed insights into the company's fiscal standing and strategic endeavors. IM Cannabis remains committed to transparency with its investors as it navigates these shifts within both the medical cannabis sector and new technological ventures.

Conclusion

IM Cannabis Corp.’s latest financial report underscores an important transitional phase for the company. With efforts made to reinvigorate their position through strategic acquisitions and the sale of non-core assets, the management appears focused on steering the company towards future sustainability and growth amidst an evolving market landscape.